“Right now, joint health is a key priority for US consumers of all ages – the majority of whom are also looking for organic solutions. Despite the importance of joint health for so many, and for organic shoppers in particular, until this point, hardly any organically-sourced joint-health solutions have been available.”
Morristown, USA, April 20, 2021 – Lonza announced today that it is expanding its UC-II® undenatured collagen ingredient line. The new UC-II® supplement is certified as made with organic collagen and Non-GMO Project Verified.
Today, consumers who want an organic joint supplement only have the option of large pills that need to be taken multiple times a day, which is often inconvenient and represents a compliance challenge. The UC-II® undenatured type II collagen addresses these issues by introducing its consumer-friendly once-a-day dose to the organic joint-health market.
Backed by three clinical studies, this patented ingredient works with the immune system to allow new joint tissue to be formed, thereby helping to improve the function and comfort of the joints1-3. This combination of efficacy and convenience has provided supplement companies with a unique consumer-friendly alternative solution to break through a crowded joint health marketplace. With the addition of a Non-GMO Project Verified, made with Organic Collagen form of the UC-II® ingredient, Lonza continues to help dietary supplement manufacturers differentiate their product in the growing organic category.
The new UC-II® Non-GMO Made with Organic Collagen is made with 93% organic ingredients, supporting the efforts of formulators to reach 95% organic material in the finished product to secure the USDA organic seal on the finished product.
The UC-II® collagen is an FDA-NDI notified ingredient and is manufactured in the United States at a state-of-the-art, FDA-registered, and food GMP-certified facility in South Carolina. The Lonza facility is certified organic by Oregon Tilth under the USDA organic regulations 7 CFR Part 205.
The new ingredient will be available for sale in the US only — interested parties can visit website.
1. Lugo JP, et al. Nutr J. 2016;15:14.
2. Lugo JP, et al. J Int Soc Sports Nutr. 2013;10:48.
3. Crowley DC, et al. J Med Sci. 2009;6:312.
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.
Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.
Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 8929
victoria.morgan@lonza.com
Dirk Oehlers
Investor Relations
Lonza Group Ltd
Tel +41 79 421 1609
dirk.oehlers@lonza.com
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.